EISAI LIMITED

🇮🇪Ireland

Country: 🇮🇪Ireland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Phase 1

Completed

Conditions: Solid Malignant Tumors
Osteosarcoma
Differentiated Thyroid Cancer (DTC)
Tumors

Interventions: Drug: Lenvatinib
Drug: Ifosfamide
Drug: Etoposide

First Posted Date: 2015-05-04

Last Posted Date: 2023-07-11

Lead Sponsor: Eisai Limited

Target Recruit Count: 117

Registration Number: NCT02432274

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇫🇷
Centre Oscar Lambret Lille, Lille, Rhone, France
🇫🇷
CHU de Toulouse - Hopital des Enfants, Toulouse, France

and more 16 locations

Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.

Completed

Conditions: Severe Chronic Pain
Pain Management

First Posted Date: 2014-10-20

Last Posted Date: 2018-10-25

Lead Sponsor: Eisai Limited

Target Recruit Count: 219

Registration Number: NCT02268812

European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)

Completed

Conditions: Lennox-Gastaut Syndrome

First Posted Date: 2013-11-25

Last Posted Date: 2016-05-04

Lead Sponsor: Eisai Limited

Target Recruit Count: 109

Registration Number: NCT01991041

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Eribulin-LF

First Posted Date: 2013-09-18

Last Posted Date: 2019-07-23

Lead Sponsor: Eisai Limited

Target Recruit Count: 62

Registration Number: NCT01945710

Locations: 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧
UCL Cancer Institute, London, United Kingdom

and more 1 locations

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3

Completed

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Drug: Lenvatinib
Drug: Sorafenib

First Posted Date: 2013-01-04

Last Posted Date: 2022-04-05

Lead Sponsor: Eisai Limited

Target Recruit Count: 954

Registration Number: NCT01761266

Locations: 🇬🇧
Facility # 3, London, Greater London, United Kingdom
🇬🇧
Facility # 2, London, Greater London, United Kingdom
🇰🇷
Facility # 6, Seoul, Korea, Republic of

and more 5 locations

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Malignant Solid Tumour
Ovarian Cancer
B-cell Malignancy, Low-grade
Triple Negative Breast Cancer
Advanced Melanoma

Interventions: Drug: E7449 plus carboplatin and paclitaxel
Drug: E7449 alone
Drug: E7449 plus TMZ

First Posted Date: 2012-06-13

Last Posted Date: 2023-06-18

Lead Sponsor: Eisai Limited

Target Recruit Count: 41

Registration Number: NCT01618136

Locations: 🇬🇧
King's College London Guy's Hospital Campus, London, United Kingdom
🇬🇧
Newcastle Upon Tyne NHS Foundation Trust, Newcastle Upon Tyne And Wear, United Kingdom

A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures

Phase 4

Terminated

Conditions: Epilepsy

Interventions: Drug: Zonisamide at targeted daily doses of 100-500 mg/day
Drug: Placebo administered to match targeted daily doses of 100-500 mg/day

First Posted Date: 2012-03-07

Last Posted Date: 2016-01-08

Lead Sponsor: Eisai Limited

Target Recruit Count: 41

Registration Number: NCT01546688

Locations: 🇩🇪
Asklepiosklinik Barmbek, Hamburg, Germany
🇩🇪
Georg-August-Universiat Gottingen, Gottingen, Germany
🇩🇪
Clinical Research Hamburg, Hamburg, Germany

and more 33 locations

A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel

Phase 1

Completed

Conditions: Central Nervous System

Interventions: Drug: alcohol + placebo
Drug: alcohol + perampanel
Drug: perampanel + alcohol
Drug: placebo + alcohol

First Posted Date: 2012-02-13

Last Posted Date: 2012-02-13

Lead Sponsor: Eisai Limited

Target Recruit Count: 59

Registration Number: NCT01531920

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Type Dementia

Interventions: Drug: E2020
Drug: Placebo

First Posted Date: 2011-07-27

Last Posted Date: 2017-03-08

Lead Sponsor: Eisai Limited

Target Recruit Count: 260

Registration Number: NCT01404169

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳
Beijing Huilongguan Hospital, Beijing, Beijing, China
🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China

and more 29 locations

A Confirmation Study of Eribulin in Combination With Capecitabine

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Eribulin mesylate
Drug: Capecitabine

First Posted Date: 2011-03-25

Last Posted Date: 2021-01-11

Lead Sponsor: Eisai Limited

Target Recruit Count: 76

Registration Number: NCT01323530

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy